0.05Open0.05Pre Close0 Volume105 Open Interest6.00Strike Price0.00Turnover159.76%IV49.06%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0258Delta0.0135Gamma233.60Leverage Ratio-0.0062Theta-0.0002Rho-6.02Eff Leverage0.0017Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet